NCT00865943View on ClinicalTrials.gov

A Relative Bioavailability Study of Citalopram HBr 10 mg Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

August 31, 2003

Study Completion Date

August 31, 2003

Conditions
Healthy
Interventions
DRUG

Citalopram HBr eq. 10 mg tablets, single dose

A: Experimental Subjects received Purepac formulated products under fasting conditions

DRUG

CELEXATM 10 mg tablets, single dose

B: Active comparator Subjects received Forest Pharmaceuticals, Inc. marketed products under fasting conditions

Trial Locations (1)

58102

PRACS Institute, Ltd., Fargo

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY